

12-14-00

A

Attorney Docket No.: 3469.234-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Sir:

This is a request for filing a divisional application under 37 C.F.R. 1.53(b) of
Applicant(s): Rasmussen et al.

Title: A Cellulase Preparation Comprising An Endoglucanase Enzyme

60 pages of specification 2 sheets of Formal Drawings

3 sheets of Declaration and Power of Attorney

14 sheets of Sequence Listing

[x] The filing fee is calculated as follows:

Basic Fee:	\$710.00
Total Claims: $23 - 20 = 3 \times 18 =$	\$54
Independent Claims: $4 - 3 = 1 \times 80 =$	\$80
Total Fee:	\$844.00

Priority of Danish application nos. 1159/90 and 736/91 filed May 9, 1990 and April 22, 1991, respectively, is claimed under 35 U.S.C. 119.

The benefit of US application nos. 07/946,489, 08/389,423 and 09/189,028 filed November 25, 1992, February 14, 1995 and November 10, 1998, respectively, and of PCT application no. PCT/DK91/00123 filed May 8, 1991 is claimed under 35 U.S.C. 120.


Direct all correspondence to:

Customer Number **25908**



25908

PATENT TRADEMARK OFFICE



[illegible]

Chris J. Lambros

Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Commissioner for Patents
Washington, DC 20231



Re: U.S. Patent Application for
Title: A Cellulase Preparation Comprising An Endoglucanase Enzyme
Applicants: Rasmussen et al.

Sir:

Express Mail Label No.


Date of Deposit: December 13, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
6. Information Disclosure Statement
7. Form PTO-1449
8. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Kelley O'Patry
(Name of person mailing paper(s) or fee)


(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123